Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Generic Pharmaceutical 172

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 172

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Malignant Mesothelioma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Glomerulonephritis. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 18, 2023

According to Globaldata, it is involved in 34 clinical trials, of which 20 were completed, 1 is ongoing, and 13 were terminated. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

XTalks

AUGUST 2, 2023

With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. billion ($3.65 billion ($2.85 billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98